{
  "success": true,
  "decomposedCriteria": [
    {
      "criterionId": "INC_I1",
      "originalText": "Participant must be \u2265 18 years of age",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a single, straightforward demographic requirement. It is represented as a single atomic node with a numeric constraint.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "atomic",
        "atomicText": "Age >= 18 years",
        "omopTable": "observation",
        "numericConstraintStructured": {
          "value": 18,
          "operator": ">=",
          "unit": "years",
          "parameter": "age"
        },
        "strategy": "This is a standard demographic requirement to ensure the participant is legally an adult for consent and safety reasons.",
        "clinicalCategory": "demographics",
        "queryableStatus": "fully_queryable"
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "6.2.1\nInclusion Criteria\nPatients that meet the following eligibility criteria will be included:\n\u2022 Participant must be \u2265 18 years of age",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I2",
      "originalText": "Written informed consent and written documentation, in accordance with the relevant country and local privacy requirements, had been obtained prior to any study procedures",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion consists of two related documentation requirements ('Written informed consent' AND 'written documentation') that must both be completed before a specific time point ('prior to any study procedures'). This is modeled as an AND operator for the two documentation types, which is then wrapped in a temporal BEFORE operator.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "temporal",
        "temporalConstraint": {
          "operator": "BEFORE",
          "anchor": "any study procedures"
        },
        "operand": {
          "nodeId": "1",
          "nodeType": "operator",
          "operator": "AND",
          "operands": [
            {
              "nodeId": "1a",
              "nodeType": "atomic",
              "atomicText": "Written informed consent obtained in accordance with relevant country and local privacy requirements",
              "omopTable": "observation",
              "strategy": "Confirms patient has formally agreed to participate in the study according to regulatory standards. This is a procedural check.",
              "clinicalCategory": "diagnostic_confirmation",
              "queryableStatus": "screening_only"
            },
            {
              "nodeId": "1b",
              "nodeType": "atomic",
              "atomicText": "Written documentation obtained in accordance with relevant country and local privacy requirements",
              "omopTable": "observation",
              "strategy": "Confirms all necessary privacy and study-related documentation is complete as per local regulations. This is a procedural check.",
              "clinicalCategory": "diagnostic_confirmation",
              "queryableStatus": "screening_only"
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "\u2022 Participant must be \u2265 18 years of age\n\u2022\nWritten informed consent and written documentation, in accordance with the\nrelevant country and local privacy requirements, had been obtained prior to\nany study procedures",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I3",
      "originalText": "Had used artificial tears for dry eyes within the past year",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "This criterion is a single condition with a temporal constraint. It is decomposed into a temporal node that specifies 'within the past year', which in turn wraps a single atomic node representing the use of artificial tears for dry eyes.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "temporal",
        "temporalConstraint": {
          "operator": "WITHIN",
          "anchor": "current_date",
          "value": 1,
          "unit": "year"
        },
        "operand": {
          "nodeId": "1a",
          "nodeType": "atomic",
          "atomicText": "Used artificial tears for dry eyes",
          "omopTable": "drug_exposure",
          "timeConstraint": "within the past year",
          "timeFrameStructured": {
            "value": 1,
            "unit": "year",
            "operator": "within",
            "relativeEvent": "current_date"
          },
          "strategy": "Query for drug exposure records for 'artificial tears' and link them to a 'dry eyes' condition to confirm the indication.",
          "clinicalCategory": "prior_therapy",
          "queryableStatus": "fully_queryable"
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "relevant country and local privacy requirements, had been obtained prior to\nany study procedures\n\u2022\nHad used artificial tears for dry eyes within the past year",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I4",
      "originalText": "Females of childbearing potential, with a negative pregnancy test result at Screening; these patients must have been currently using a reliable form of birth control and have agreed to use a reliable form of birth control for the duration of the study",
      "type": "Inclusion",
      "logicOperator": "IMPLICATION",
      "decompositionStrategy": "The criterion is structured as a conditional requirement, best represented by an IMPLICATION operator. The condition is being a 'Female of childbearing potential'. If this condition is met, a set of three requirements, connected by AND, must also be met: a negative pregnancy test, current use of reliable birth control, and agreement to continue its use.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "IMPLICATION",
        "condition": {
          "nodeId": "1",
          "nodeType": "atomic",
          "atomicText": "Female of childbearing potential",
          "omopTable": "observation",
          "strategy": "Identifies the specific sub-population to which the pregnancy and contraception requirements apply.",
          "clinicalCategory": "demographics",
          "queryableStatus": "requires_manual"
        },
        "requirement": {
          "nodeId": "2",
          "nodeType": "operator",
          "operator": "AND",
          "operands": [
            {
              "nodeId": "2a",
              "nodeType": "operator",
              "operator": "NOT",
              "operands": [
                {
                  "nodeId": "2a1",
                  "nodeType": "atomic",
                  "atomicText": "Positive pregnancy test result at Screening",
                  "omopTable": "measurement",
                  "timeConstraint": "at Screening",
                  "timeFrameStructured": {
                    "value": 0,
                    "unit": "",
                    "operator": "during",
                    "relativeEvent": "Screening"
                  },
                  "strategy": "A negative test result is required. This is modeled as the absence of a positive test result.",
                  "clinicalCategory": "safety_exclusion",
                  "queryableStatus": "fully_queryable"
                }
              ]
            },
            {
              "nodeId": "2b",
              "nodeType": "atomic",
              "atomicText": "Currently using a reliable form of birth control",
              "omopTable": "observation",
              "strategy": "Confirms the patient is using an acceptable contraceptive method at the time of screening.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "requires_manual"
            },
            {
              "nodeId": "2c",
              "nodeType": "atomic",
              "atomicText": "Agreed to use a reliable form of birth control for the duration of the study",
              "omopTable": "observation",
              "strategy": "Documents the patient's commitment to maintain contraception throughout the study, typically captured in the informed consent form.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "screening_only"
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "\u2022\nHad used artificial tears for dry eyes within the past year\n\u2022 Females of childbearing potential, with a negative pregnancy test result at\nScreening; these patients must have been currently using a reliable form of\nbirth control and have agreed to use a reliable form of birth control for the\nduration of the study",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I5",
      "originalText": "OSDI score of \u2265 18 and \u2264 65 (based upon a 0 to 100 scale) at Screening and Baseline Visits",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion specifies a required range for the OSDI score that must be met at two distinct time points: Screening and Baseline. This is a conjunction, modeled with a root AND operator, connecting two separate atomic conditions, one for each visit.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "OSDI score of \u2265 18 and \u2264 65 at Screening Visit",
            "omopTable": "measurement",
            "timeConstraint": "at Screening Visit",
            "numericRangeStructured": {
              "min": 18,
              "max": 65,
              "unit": "score",
              "parameter": "OSDI score"
            },
            "strategy": "Measures the Ocular Surface Disease Index (OSDI) score at the Screening visit to confirm patient has moderate to severe disease symptoms.",
            "clinicalCategory": "disease_indication",
            "queryableStatus": "fully_queryable"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "OSDI score of \u2265 18 and \u2264 65 at Baseline Visit",
            "omopTable": "measurement",
            "timeConstraint": "at Baseline Visit",
            "numericRangeStructured": {
              "min": 18,
              "max": 65,
              "unit": "score",
              "parameter": "OSDI score"
            },
            "strategy": "Confirms the Ocular Surface Disease Index (OSDI) score remains within the eligible range at the Baseline visit prior to randomization or treatment.",
            "clinicalCategory": "disease_indication",
            "queryableStatus": "fully_queryable"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "birth control and have agreed to use a reliable form of birth control for the\nduration of the study\n\u2022\nOSDI score of \u2265 18 and \u2264 65 (based upon a 0 to 100 scale) at Screening and\nBaseline Visits",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I6",
      "originalText": "Three consecutive tear break-up time (TBUT) tests \u2264 10 seconds in at least 1 eye at Screening Visit",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is decomposed by first applying the overarching temporal context 'at Screening Visit' using a temporal node. The core requirement 'in at least 1 eye' is then modeled as an OR operator with two operands, one for the left eye and one for the right. The complex condition 'Three consecutive ... tests \u2264 10 seconds' is treated as a single atomic unit within each operand.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "temporal",
        "temporalConstraint": {
          "operator": "DURING",
          "anchor": "Screening Visit"
        },
        "operand": {
          "nodeId": "1a",
          "nodeType": "operator",
          "operator": "OR",
          "operands": [
            {
              "nodeId": "1a1",
              "nodeType": "atomic",
              "atomicText": "Three consecutive tear break-up time (TBUT) tests \u2264 10 seconds in the left eye",
              "omopTable": "measurement",
              "numericConstraintStructured": {
                "value": 10,
                "operator": "<=",
                "unit": "seconds",
                "parameter": "Tear break-up time (TBUT)"
              },
              "strategy": "Requires identifying a series of three consecutive TBUT measurements for the left eye, where each measurement value is less than or equal to 10 seconds. This may require manual review or a complex query with window functions.",
              "clinicalCategory": "diagnostic_confirmation",
              "queryableStatus": "partially_queryable",
              "clinicalConceptGroup": "tbut_dry_eye_confirmation"
            },
            {
              "nodeId": "1a2",
              "nodeType": "atomic",
              "atomicText": "Three consecutive tear break-up time (TBUT) tests \u2264 10 seconds in the right eye",
              "omopTable": "measurement",
              "numericConstraintStructured": {
                "value": 10,
                "operator": "<=",
                "unit": "seconds",
                "parameter": "Tear break-up time (TBUT)"
              },
              "strategy": "Requires identifying a series of three consecutive TBUT measurements for the right eye, where each measurement value is less than or equal to 10 seconds. This may require manual review or a complex query with window functions.",
              "clinicalCategory": "diagnostic_confirmation",
              "queryableStatus": "partially_queryable",
              "clinicalConceptGroup": "tbut_dry_eye_confirmation"
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "OSDI score of \u2265 18 and \u2264 65 (based upon a 0 to 100 scale) at Screening and\nBaseline Visits\n\u2022 Three consecutive tear break-up time (TBUT) tests \u2264 10 seconds in at least\n1 eye at Screening Visit",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I7",
      "originalText": "Grade 1 to 4 (modified National Eye Institute [NEI] Grid, score range = 0 to 5) staining in at least 1 area of the cornea (5 areas examined) or conjunctiva (6 areas examined) that was related to dry eye in at least 1 eye at both at Screening and Baseline Visits",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is structured as a conjunction (AND) over two time points: Screening and Baseline. At each time point, the requirement is a disjunction (OR) between staining found in the cornea or the conjunctiva. This leads to a top-level AND operator, with two OR operator children, each representing a visit.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "1a",
                "nodeType": "atomic",
                "atomicText": "Grade 1 to 4 corneal staining (modified NEI Grid) related to dry eye in at least 1 eye at Screening Visit",
                "omopTable": "observation",
                "timeConstraint": "at Screening Visit",
                "numericRangeStructured": {
                  "min": 1,
                  "max": 4,
                  "unit": "",
                  "parameter": "Corneal staining score (modified NEI Grid)"
                },
                "strategy": "This is a key inclusion criterion based on a specific ocular surface staining assessment performed at the Screening visit, indicating a sufficient level of dry eye disease in the cornea.",
                "clinicalCategory": "diagnostic_confirmation",
                "queryableStatus": "requires_manual",
                "clinicalConceptGroup": "ocular_surface_staining"
              },
              {
                "nodeId": "1b",
                "nodeType": "atomic",
                "atomicText": "Grade 1 to 4 conjunctival staining (modified NEI Grid) related to dry eye in at least 1 eye at Screening Visit",
                "omopTable": "observation",
                "timeConstraint": "at Screening Visit",
                "numericRangeStructured": {
                  "min": 1,
                  "max": 4,
                  "unit": "",
                  "parameter": "Conjunctival staining score (modified NEI Grid)"
                },
                "strategy": "This is a key inclusion criterion based on a specific ocular surface staining assessment performed at the Screening visit, indicating a sufficient level of dry eye disease in the conjunctiva.",
                "clinicalCategory": "diagnostic_confirmation",
                "queryableStatus": "requires_manual",
                "clinicalConceptGroup": "ocular_surface_staining"
              }
            ]
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "Grade 1 to 4 corneal staining (modified NEI Grid) related to dry eye in at least 1 eye at Baseline Visit",
                "omopTable": "observation",
                "timeConstraint": "at Baseline Visit",
                "numericRangeStructured": {
                  "min": 1,
                  "max": 4,
                  "unit": "",
                  "parameter": "Corneal staining score (modified NEI Grid)"
                },
                "strategy": "This confirms the persistence of the ocular surface staining from Screening to the Baseline visit, ensuring the condition is stable and present at the start of the study.",
                "clinicalCategory": "diagnostic_confirmation",
                "queryableStatus": "requires_manual",
                "clinicalConceptGroup": "ocular_surface_staining"
              },
              {
                "nodeId": "2b",
                "nodeType": "atomic",
                "atomicText": "Grade 1 to 4 conjunctival staining (modified NEI Grid) related to dry eye in at least 1 eye at Baseline Visit",
                "omopTable": "observation",
                "timeConstraint": "at Baseline Visit",
                "numericRangeStructured": {
                  "min": 1,
                  "max": 4,
                  "unit": "",
                  "parameter": "Conjunctival staining score (modified NEI Grid)"
                },
                "strategy": "This confirms the persistence of the ocular surface staining from Screening to the Baseline visit, ensuring the condition is stable and present at the start of the study.",
                "clinicalCategory": "diagnostic_confirmation",
                "queryableStatus": "requires_manual",
                "clinicalConceptGroup": "ocular_surface_staining"
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "1 eye at Screening Visit\n\u2022 Grade 1 to 4 (modified National Eye Institute [NEI] Grid, score range = 0 to 5)\nstaining in at least 1 area of the cornea (5 areas examined) or conjunctiva\n(6 areas examined) that was related to dry eye in at least 1 eye at both at\nScreening and Baseline Visits",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I8",
      "originalText": "Was able/agreed to continue to wear existing current spectacle correction during the study period (if applicable)",
      "type": "Inclusion",
      "logicOperator": "IMPLICATION",
      "decompositionStrategy": "The criterion is a conditional requirement, identified by the phrase '(if applicable)'. This is modeled using an IMPLICATION operator. The condition is that the subject uses spectacle correction, and the requirement is their agreement to continue wearing them during the study.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "IMPLICATION",
        "condition": {
          "nodeId": "1",
          "nodeType": "atomic",
          "atomicText": "Uses current spectacle correction",
          "omopTable": "observation",
          "strategy": "Identifies subjects for whom wearing spectacles is applicable.",
          "clinicalCategory": "safety_exclusion",
          "queryableStatus": "screening_only"
        },
        "requirement": {
          "nodeId": "2",
          "nodeType": "atomic",
          "atomicText": "Able and agreed to continue to wear existing current spectacle correction during the study period",
          "omopTable": "observation",
          "timeConstraint": "during the study period",
          "timeFrameStructured": {
            "value": 0,
            "unit": "",
            "operator": "during",
            "relativeEvent": "study_period"
          },
          "strategy": "Confirms subject compliance with maintaining consistent visual correction for study assessments.",
          "clinicalCategory": "diagnostic_confirmation",
          "queryableStatus": "screening_only"
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "(6 areas examined) that was related to dry eye in at least 1 eye at both at\nScreening and Baseline Visits\n\u2022 Was able/agreed to continue to wear existing current spectacle correction\nduring the study period (if applicable)",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I9",
      "originalText": "Currently corrected distance visual acuity of at least 20/32 Snellen equivalent in each eye using the 3-meter LogMar chart, with existing spectacle correction (if necessary) at Screening Visit",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion requires a specific visual acuity threshold to be met in 'each eye'. This phrasing implies a logical AND, where the condition must be true for the right eye AND true for the left eye. Therefore, the tree will have a root AND operator with two atomic operands, one for each eye.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Corrected distance visual acuity of at least 20/32 Snellen equivalent in the right eye at Screening Visit",
            "omopTable": "measurement",
            "valueConstraint": "LogMAR <= 0.2",
            "timeConstraint": "at Screening Visit",
            "timeFrameStructured": {
              "value": 0,
              "unit": "",
              "operator": "during",
              "relativeEvent": "Screening Visit"
            },
            "numericConstraintStructured": {
              "value": 0.2,
              "operator": "<=",
              "unit": "LogMAR",
              "parameter": "Corrected distance visual acuity, right eye"
            },
            "strategy": "Ensures adequate visual function in the right eye. The test is performed using a 3-meter LogMar chart. A Snellen score of 20/32 is equivalent to a LogMAR score of 0.2, and 'at least' this acuity means a LogMAR score of 0.2 or lower (better vision).",
            "clinicalCategory": "organ_function",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "visual_acuity"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Corrected distance visual acuity of at least 20/32 Snellen equivalent in the left eye at Screening Visit",
            "omopTable": "measurement",
            "valueConstraint": "LogMAR <= 0.2",
            "timeConstraint": "at Screening Visit",
            "timeFrameStructured": {
              "value": 0,
              "unit": "",
              "operator": "during",
              "relativeEvent": "Screening Visit"
            },
            "numericConstraintStructured": {
              "value": 0.2,
              "operator": "<=",
              "unit": "LogMAR",
              "parameter": "Corrected distance visual acuity, left eye"
            },
            "strategy": "Ensures adequate visual function in the left eye. The test is performed using a 3-meter LogMar chart. A Snellen score of 20/32 is equivalent to a LogMAR score of 0.2, and 'at least' this acuity means a LogMAR score of 0.2 or lower (better vision).",
            "clinicalCategory": "organ_function",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "visual_acuity"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "during the study period (if applicable)\n\u2022 Currently corrected distance visual acuity of at least 20/32 Snellen equivalent\nin each eye using the 3-meter LogMar chart, with existing spectacle correction\n(if necessary) at Screening Visit",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I10",
      "originalText": "If using any form of topical ophthalmic cyclosporine (i.e., RESTASIS\u00ae), lifitegrast 5% ophthalmic solution (Xiidra\u00ae), participants must be using the drops for \u2265 90 days prior to the Screening Visit and plan to continue without change for the duration of the study",
      "type": "Inclusion",
      "logicOperator": "IMPLICATION",
      "decompositionStrategy": "The criterion is a conditional statement ('If...then...'), which is modeled using the IMPLICATION operator. The 'if' condition is an OR of two specific drug therapies. The 'then' requirement is an AND of two conditions: a minimum duration of use and a plan to continue without change, where 'without change' is explicitly modeled using the NOT operator.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "IMPLICATION",
        "condition": {
          "nodeId": "1",
          "nodeType": "operator",
          "operator": "OR",
          "operands": [
            {
              "nodeId": "1a",
              "nodeType": "atomic",
              "atomicText": "Using topical ophthalmic cyclosporine (e.g., RESTASIS\u00ae)",
              "omopTable": "drug_exposure",
              "strategy": "Identifies patients on a specific topical ophthalmic immunomodulator.",
              "clinicalCategory": "prior_therapy",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "topical_ophthalmic_immunomodulators"
            },
            {
              "nodeId": "1b",
              "nodeType": "atomic",
              "atomicText": "Using lifitegrast 5% ophthalmic solution (e.g., Xiidra\u00ae)",
              "omopTable": "drug_exposure",
              "strategy": "Identifies patients on a specific topical ophthalmic immunomodulator.",
              "clinicalCategory": "prior_therapy",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "topical_ophthalmic_immunomodulators"
            }
          ]
        },
        "requirement": {
          "nodeId": "2",
          "nodeType": "operator",
          "operator": "AND",
          "operands": [
            {
              "nodeId": "2a",
              "nodeType": "atomic",
              "atomicText": "Using the qualifying ophthalmic drops for at least 90 days prior to the Screening Visit",
              "omopTable": "drug_exposure",
              "timeConstraint": "Duration of use >= 90 days, occurring prior to the Screening Visit",
              "numericConstraintStructured": {
                "value": 90,
                "operator": ">=",
                "unit": "days",
                "parameter": "duration of use"
              },
              "strategy": "Ensures stable, long-term use of the qualifying medication before study entry.",
              "clinicalCategory": "prior_therapy",
              "queryableStatus": "fully_queryable"
            },
            {
              "nodeId": "2b",
              "nodeType": "operator",
              "operator": "NOT",
              "operands": [
                {
                  "nodeId": "2b1",
                  "nodeType": "atomic",
                  "atomicText": "Plan to change use of topical ophthalmic immunomodulators for the duration of the study",
                  "omopTable": "observation",
                  "strategy": "Confirms patient intent to maintain a stable therapeutic regimen during the study. This is determined via patient interview.",
                  "clinicalCategory": "prior_therapy",
                  "queryableStatus": "requires_manual"
                }
              ]
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "(if necessary) at Screening Visit\n\u2022\nIf using any form of topical ophthalmic cyclosporine (i.e., RESTASIS\u00ae),\nlifitegrast 5% ophthalmic solution (Xiidra\u00ae), participants must be using the\ndrops for \u2265 90 days prior to the Screening Visit and plan to continue without\nchange for the duration of the study",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I11",
      "originalText": "Intraocular pressure (IOP) \u2264 21 mmHg in both eyes at Screening Visit for patients with primary open-angle glaucoma or ocular hypertension (OHT). Patients with primary open-angle glaucoma or OHT were included provided they were on stable monotherapy bilaterally with IOP controlled (\u2264 21 mmHg) in both eyes. Any topical IOP-lowering medications must have had a start date of \u2265 3 months prior to Screening Visit date and dosage that was not expected to change during the study.",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion defines a single cohort of patients with specific characteristics, so it is decomposed as a series of AND conditions. The core requirements are: a diagnosis of glaucoma or OHT, controlled intraocular pressure, and being on a specific type of stable monotherapy. The definition of 'stable' is further broken down into sub-conditions related to treatment duration and dosage.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "1a",
                "nodeType": "atomic",
                "atomicText": "Primary open-angle glaucoma",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies patients with the primary disease indication.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queyable",
                "clinicalConceptGroup": "glaucoma_oht"
              },
              {
                "nodeId": "1b",
                "nodeType": "atomic",
                "atomicText": "Ocular hypertension (OHT)",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies patients with the alternative disease indication.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "glaucoma_oht"
              }
            ]
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Intraocular pressure (IOP) \u2264 21 mmHg in both eyes at Screening Visit",
            "omopTable": "measurement",
            "timeConstraint": "at Screening Visit",
            "numericConstraintStructured": {
              "value": 21,
              "operator": "<=",
              "unit": "mmHg",
              "parameter": "Intraocular pressure"
            },
            "strategy": "Confirms IOP is controlled at baseline. 'Both eyes' implies two measurements meeting the criteria.",
            "clinicalCategory": "organ_function",
            "queryableStatus": "partially_queryable"
          },
          {
            "nodeId": "3a",
            "nodeType": "atomic",
            "atomicText": "Receiving bilateral monotherapy with a topical IOP-lowering medication",
            "omopTable": "drug_exposure",
            "strategy": "Patient must be on a single IOP-lowering medication in both eyes, and not multiple.",
            "clinicalCategory": "prior_therapy",
            "queryableStatus": "partially_queryable"
          },
          {
            "nodeId": "3b",
            "nodeType": "temporal",
            "temporalConstraint": {
              "operator": "BEFORE",
              "anchor": "Screening Visit",
              "value": 3,
              "unit": "months"
            },
            "operand": {
              "nodeId": "3b1",
              "nodeType": "atomic",
              "atomicText": "Start date of topical IOP-lowering medication",
              "omopTable": "drug_era",
              "strategy": "Ensures the patient's therapy has been stable for a minimum duration before the study.",
              "clinicalCategory": "prior_therapy",
              "queryableStatus": "fully_queryable"
            }
          },
          {
            "nodeId": "3c",
            "nodeType": "atomic",
            "atomicText": "Dosage of topical IOP-lowering medication is not expected to change during the study",
            "omopTable": "observation",
            "strategy": "Confirms the stability of the current treatment regimen, which is a prospective assessment.",
            "clinicalCategory": "prior_therapy",
            "queryableStatus": "requires_manual"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 16,
        "textSnippet": "change for the duration of the study\n\u2022\nIntraocular pressure (IOP) \u2264 21 mmHg in both eyes at Screening Visit for\npatients with primary open-angle glaucoma or ocular hypertension (OHT).\nPatients with primary open-angle glaucoma or OHT were included provided",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_I12",
      "originalText": "Was able to follow study instructions and was likely to complete all required visits",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion consists of two independent conditions joined by 'and', indicating a root AND operator. Both conditions are subjective assessments of the patient's ability to comply with the study protocol, making them atomic nodes that require manual review.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Able to follow study instructions",
            "omopTable": "observation",
            "strategy": "This is a subjective assessment by the investigator to ensure the patient can understand and adhere to the study protocol.",
            "clinicalCategory": "performance_status",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Likely to complete all required study visits",
            "omopTable": "observation",
            "strategy": "This is a subjective assessment by the investigator regarding the patient's reliability and commitment to completing the entire study.",
            "clinicalCategory": "performance_status",
            "queryableStatus": "requires_manual"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 17,
        "textSnippet": "of \u2265 3 months prior to Screening Visit date and dosage that was not expected\nto change during the study.\n\u2022 Was able to follow study instructions and was likely to complete all required\nvisits",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E1",
      "originalText": "Have uncontrolled severe systemic disease that, in the assessment of the investigator, would put safety of the participant at risk through participation, or which would prevent or confound protocol-specified assessments (e.g., hypertension and diabetes, Sj\u00f6gren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, immunodeficiency disease, etc.)",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion describes a single, complex reason for exclusion, which is decomposed into a primary logical AND structure. A patient is excluded if they have an 'uncontrolled severe systemic disease' AND that disease results in one of several negative outcomes. These outcomes (posing a safety risk, preventing assessments, or confounding assessments) are linked by an OR operator. The entire condition relies on the investigator's judgment, so all atomic nodes are marked as `requires_manual`. The specific diseases listed are treated as examples that inform the primary condition, not as separate, independent logical clauses.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Presence of an uncontrolled severe systemic disease",
            "omopTable": "observation",
            "strategy": "This is a high-level assessment by the investigator that a patient's systemic disease is both severe and not adequately managed. Examples of such diseases mentioned in the protocol include hypertension, diabetes, Sj\u00f6gren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, and immunodeficiency disease.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "Systemic disease would put the safety of the participant at risk through participation",
                "omopTable": "observation",
                "strategy": "This is the investigator's clinical judgment that the patient's participation in the trial would pose an unacceptable safety risk due to their underlying systemic disease.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "requires_manual"
              },
              {
                "nodeId": "2b",
                "nodeType": "atomic",
                "atomicText": "Systemic disease would prevent protocol-specified assessments",
                "omopTable": "observation",
                "strategy": "This is the investigator's assessment that the patient's disease or its symptoms would make it impossible to perform required study procedures or assessments.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "requires_manual"
              },
              {
                "nodeId": "2c",
                "nodeType": "atomic",
                "atomicText": "Systemic disease would confound protocol-specified assessments",
                "omopTable": "observation",
                "strategy": "This is the investigator's assessment that the patient's disease or its symptoms would interfere with the interpretation of study data, compromising the scientific integrity of the assessments.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "requires_manual"
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 17,
        "textSnippet": "6.2.2\nExclusion Criteria\nPatients that have any of the following criteria will be excluded:\n\u2022 Have uncontrolled severe systemic disease that, in the assessment of the\ninvestigator, would put safety of the participant at risk through participation, or\nwhich would prevent or confound protocol-specified assessments\n(e.g., hypertension and diabetes, Sj\u00f6gren's syndrome, rheumatoid arthritis,\nsystemic lupus erythematosus, immunodeficiency disease, etc.)",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E2",
      "originalText": "Known allergy or sensitivity to the study products or their components",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion is decomposed into an OR condition with two clauses. The first clause covers allergy or sensitivity to the study products themselves, and the second covers allergy or sensitivity to their components. A patient is ineligible if either of these conditions is met.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Known allergy or sensitivity to the study products",
            "omopTable": "observation",
            "strategy": "This is a standard safety exclusion to prevent adverse reactions in patients with known hypersensitivity to the investigational drug(s). This requires mapping protocol-specific study products to clinical concepts.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "study_product_hypersensitivity"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Known allergy or sensitivity to the components of the study products",
            "omopTable": "observation",
            "strategy": "This extends the safety exclusion to include excipients or other non-active ingredients in the study product formulation, which can also cause allergic reactions. This is difficult to query as it requires knowledge of the full drug formulation.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "study_product_hypersensitivity"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 17,
        "textSnippet": "systemic lupus erythematosus, immunodeficiency disease, etc.)\n\u2022 Known allergy or sensitivity to the study products or their components",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E3",
      "originalText": "Females who were pregnant, nursing, or planning a pregnancy",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion describes a population of females who meet one or more of three related conditions. This is modeled as a primary AND condition for being female, combined with a nested OR group for the three states: pregnant, nursing, or planning a pregnancy.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Female",
            "omopTable": "person",
            "strategy": "Filter for patients who are female.",
            "clinicalCategory": "demographics",
            "queryableStatus": "fully_queryable"
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "Pregnant",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies patients with a condition or observation of pregnancy.",
                "clinicalCategory": "demographics",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "pregnancy_status"
              },
              {
                "nodeId": "2b",
                "nodeType": "atomic",
                "atomicText": "Nursing",
                "omopTable": "observation",
                "strategy": "Identifies patients who are currently nursing/lactating. This may require manual confirmation.",
                "clinicalCategory": "demographics",
                "queryableStatus": "partially_queryable",
                "clinicalConceptGroup": "pregnancy_status"
              },
              {
                "nodeId": "2c",
                "nodeType": "atomic",
                "atomicText": "Planning a pregnancy",
                "omopTable": "observation",
                "strategy": "Identifies patients who report planning a pregnancy. This typically requires manual confirmation.",
                "clinicalCategory": "demographics",
                "queryableStatus": "requires_manual",
                "clinicalConceptGroup": "pregnancy_status"
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 17,
        "textSnippet": "\u2022 Known allergy or sensitivity to the study products or their components\n\u2022 Females who were pregnant, nursing, or planning a pregnancy",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E4",
      "originalText": "Females of childbearing potential and who were not using a reliable method of contraception",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a conjunction of two conditions joined by 'AND'. The first condition identifies females of childbearing potential. The second is a negative condition ('not using'), which is captured using a NOT operator wrapping the positive atomic condition 'using a reliable method of contraception'.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Female of childbearing potential",
            "omopTable": "observation",
            "strategy": "Identifies the specific demographic subgroup of women who are biologically capable of becoming pregnant. This status is typically a clinical assessment.",
            "clinicalCategory": "demographics",
            "queryableStatus": "partially_queryable"
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "NOT",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "Using a reliable method of contraception",
                "omopTable": "observation",
                "strategy": "Checks for the use of effective birth control methods as specified by the protocol. The absence of this condition is required.",
                "clinicalCategory": "demographics",
                "queryableStatus": "requires_manual"
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 17,
        "textSnippet": "\u2022 Females who were pregnant, nursing, or planning a pregnancy\n\u2022 Females of childbearing potential and who were not using a reliable method of\ncontraception",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E5",
      "originalText": "Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study at Screening Visit",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion consists of two conditions linked by an 'OR' operator. The first condition is a current state ('Current enrollment'), and the second is a past state with a specific time window ('participation... within 30 days'). This structure is represented by a root OR node with two operands.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Current enrollment in an investigational drug or device study",
            "omopTable": "observation",
            "timeConstraint": "at Screening Visit",
            "timeFrameStructured": {
              "value": 0,
              "unit": "",
              "operator": "during",
              "relativeEvent": "Screening Visit"
            },
            "strategy": "Identifies concurrent participation in another clinical trial at the time of screening.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "investigational_study_participation"
          },
          {
            "nodeId": "2",
            "nodeType": "temporal",
            "temporalConstraint": {
              "operator": "WITHIN",
              "anchor": "Screening Visit",
              "value": 30,
              "unit": "days"
            },
            "operand": {
              "nodeId": "2a",
              "nodeType": "atomic",
              "atomicText": "Participation in an investigational drug or device study",
              "omopTable": "observation",
              "strategy": "Identifies recent participation in another clinical trial to avoid carry-over effects from other investigational agents.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "requires_manual",
              "clinicalConceptGroup": "investigational_study_participation"
            }
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 17,
        "textSnippet": "contraception\n\u2022\nCurrent enrollment in an investigational drug or device study or participation\nin such a study within 30 days of entry into this study at Screening Visit",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E6",
      "originalText": "Schirmer Test (with anesthesia) \u2264 2 mm in either eye at Screening Visit",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion is decomposed using an OR operator to capture the 'in either eye' logic. This creates two parallel branches, one for each eye, where meeting the Schirmer Test threshold in at least one eye satisfies the condition.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Schirmer Test (with anesthesia) result in one eye is \u2264 2 mm at Screening Visit",
            "omopTable": "measurement",
            "timeConstraint": "at Screening Visit",
            "timeFrameStructured": {
              "value": 0,
              "unit": "",
              "operator": "during",
              "relativeEvent": "Screening Visit"
            },
            "numericConstraintStructured": {
              "value": 2,
              "operator": "<=",
              "unit": "mm",
              "parameter": "Schirmer Test (with anesthesia)"
            },
            "strategy": "Confirms severe aqueous tear deficiency in the left eye as part of diagnostic confirmation for a condition like dry eye disease.",
            "clinicalCategory": "diagnostic_confirmation",
            "queryableStatus": "screening_only",
            "clinicalConceptGroup": "schirmer_test_result"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Schirmer Test (with anesthesia) result in the other eye is \u2264 2 mm at Screening Visit",
            "omopTable": "measurement",
            "timeConstraint": "at Screening Visit",
            "timeFrameStructured": {
              "value": 0,
              "unit": "",
              "operator": "during",
              "relativeEvent": "Screening Visit"
            },
            "numericConstraintStructured": {
              "value": 2,
              "operator": "<=",
              "unit": "mm",
              "parameter": "Schirmer Test (with anesthesia)"
            },
            "strategy": "Confirms severe aqueous tear deficiency in the right eye as part of diagnostic confirmation for a condition like dry eye disease.",
            "clinicalCategory": "diagnostic_confirmation",
            "queryableStatus": "screening_only",
            "clinicalConceptGroup": "schirmer_test_result"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 17,
        "textSnippet": "in such a study within 30 days of entry into this study at Screening Visit\n\u2022 Schirmer Test (with anesthesia) \u2264 2 mm in either eye at Screening Visit",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E7",
      "originalText": "Patient anticipated contact lens wear during the study, or the patient had worn contact lenses in the last 3 months prior to Screening Visit",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion is a simple OR condition, combining two scenarios related to contact lens wear. The first is a future-looking intent, and the second is a retrospective look at recent use. The tree structure is an OR operator with two child nodes representing each condition.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Anticipated contact lens wear during the study",
            "omopTable": "observation",
            "timeConstraint": "during the study",
            "timeFrameStructured": {
              "value": 0,
              "unit": "",
              "operator": "during",
              "relativeEvent": "study"
            },
            "strategy": "This is a forward-looking condition based on patient interview to prevent interference with study procedures or assessments.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "2",
            "nodeType": "temporal",
            "temporalConstraint": {
              "operator": "WITHIN",
              "anchor": "Screening Visit",
              "value": 3,
              "unit": "months"
            },
            "operand": {
              "nodeId": "2a",
              "nodeType": "atomic",
              "atomicText": "Worn contact lenses",
              "omopTable": "device_exposure",
              "timeConstraint": "in the last 3 months prior to Screening Visit",
              "timeFrameStructured": {
                "value": 3,
                "unit": "months",
                "operator": "within",
                "relativeEvent": "Screening Visit"
              },
              "strategy": "This captures recent contact lens use prior to the study, which might affect baseline measurements.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "partially_queryable"
            }
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 17,
        "textSnippet": "\u2022 Schirmer Test (with anesthesia) \u2264 2 mm in either eye at Screening Visit\n\u2022\nPatient anticipated contact lens wear during the study, or the patient had worn\ncontact lenses in the last 3 months prior to Screening Visit",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E8",
      "originalText": "Any scheduled or planned elective ocular or systemic surgery or procedure during the study, which in the investigator's opinion, may have impacted the patient's study participation",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion describes an exclusion based on a future event. It is structured as an 'A which B' pattern, which translates to 'A AND B'. 'A' is the description of the event (a planned surgery/procedure during the study), and 'B' is the investigator's assessment of its impact. The event description 'A' contains an OR condition ('ocular or systemic'), which is represented as an OR node with two atomic operands.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "1a",
                "nodeType": "atomic",
                "atomicText": "Scheduled or planned elective ocular surgery or procedure",
                "omopTable": "procedure_occurrence",
                "timeConstraint": "during the study",
                "timeFrameStructured": {
                  "value": 0,
                  "unit": "",
                  "operator": "during",
                  "relativeEvent": "study participation"
                },
                "strategy": "Identifies any planned, non-emergency eye-related surgeries or procedures that would occur during the trial period.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "requires_manual"
              },
              {
                "nodeId": "1b",
                "nodeType": "atomic",
                "atomicText": "Scheduled or planned elective systemic surgery or procedure",
                "omopTable": "procedure_occurrence",
                "timeConstraint": "during the study",
                "timeFrameStructured": {
                  "value": 0,
                  "unit": "",
                  "operator": "during",
                  "relativeEvent": "study participation"
                },
                "strategy": "Identifies any planned, non-emergency major body system surgeries or procedures that would occur during the trial period.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "requires_manual"
              }
            ]
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Investigator's opinion: surgery or procedure may impact study participation",
            "omopTable": "observation",
            "strategy": "Captures the required clinical judgment that a planned procedure would interfere with the patient's ability to participate in the study, making them ineligible.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 17,
        "textSnippet": "contact lenses in the last 3 months prior to Screening Visit\n\u2022 Any scheduled or planned elective ocular or systemic surgery or procedure\nduring the study, which in the investigator's opinion, may have impacted the\npatient's study participation",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E9",
      "originalText": "At the Screening and Baseline visits, either eye has corneal staining score of 5 in any of the 5 zones or a total score of > 19 based on the modified NEI grading scheme (score range = 0 to 5; graded in 5 zones of the cornea for a total score range of 0 to 25) or conjunctival staining score of 5 in any of the 6 zones based on the modified NEI grading scheme (score range = 0 to 5 per zone)",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion consists of three conditions linked by 'or', forming a single disjunctive clause. This is represented by a root OR operator with three atomic operands, each describing a specific ocular staining score threshold (focal corneal, total corneal, or focal conjunctival) that must be met in either eye at the screening or baseline visits.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Corneal staining score of 5 in any of the 5 zones in either eye",
            "omopTable": "observation",
            "valueConstraint": "score = 5 in any of 5 zones",
            "timeConstraint": "At Screening and Baseline visits",
            "numericConstraintStructured": {
              "value": 5,
              "operator": "=",
              "unit": "score",
              "parameter": "Maximum corneal staining score in any zone (modified NEI grading)"
            },
            "strategy": "This atomic identifies patients with severe focal corneal staining in at least one zone of either eye, which is a key indicator of severe dry eye disease.",
            "clinicalCategory": "disease_indication",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Total corneal staining score > 19 in either eye",
            "omopTable": "observation",
            "valueConstraint": "total score > 19 (out of 25)",
            "timeConstraint": "At Screening and Baseline visits",
            "numericConstraintStructured": {
              "value": 19,
              "operator": ">",
              "unit": "score",
              "parameter": "Total corneal staining score (modified NEI grading)"
            },
            "strategy": "This atomic identifies patients with severe diffuse corneal staining across all zones of either eye, another indicator of severe dry eye disease.",
            "clinicalCategory": "disease_indication",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "3",
            "nodeType": "atomic",
            "atomicText": "Conjunctival staining score of 5 in any of the 6 zones in either eye",
            "omopTable": "observation",
            "valueConstraint": "score = 5 in any of 6 zones",
            "timeConstraint": "At Screening and Baseline visits",
            "numericConstraintStructured": {
              "value": 5,
              "operator": "=",
              "unit": "score",
              "parameter": "Maximum conjunctival staining score in any zone (modified NEI grading)"
            },
            "strategy": "This atomic identifies patients with severe focal conjunctival staining, a sign of significant ocular surface disease.",
            "clinicalCategory": "disease_indication",
            "queryableStatus": "requires_manual"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 17,
        "textSnippet": "patient's study participation\n\u2022\nAt the Screening and Baseline visits, either eye has corneal staining score of 5\nin any of the 5 zones or a total score of > 19 based on the modified NEI\ngrading scheme (score range = 0 to 5; graded in 5 zones of the cornea for a\ntotal score range of 0 to 25) or conjunctival staining score of 5 in any of the",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E10",
      "originalText": "Use of systemic medications (over-the-counter, herbal, prescription, or nutritional supplements for dry eyes), which may have affected tear film or vision (including but not limited to the following: flax seed oil, fish oil, omega-3 supplements, cyclosporine, antihistamines, cholinergic agents, anticholinergics, antimuscarines, beta-blocking agents, tricyclic antidepressants, phenothiazines, estrogen-progesterone, and other estrogen derivatives), unless that medication had been used at the same dose for at least 3 months prior to screening and the dosage was not expected to change during the course of the study",
      "type": "Exclusion",
      "logicOperator": "IMPLICATION",
      "decompositionStrategy": "The criterion is a conditional exclusion, modeled with an IMPLICATION operator. The 'IF' condition (the use of specific medications) is represented by an OR group of all listed drug classes. The 'THEN' requirement for eligibility (the 'unless' clause) is an AND of two stability conditions: a stable dose for 3+ months and no expected dosage change.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "IMPLICATION",
        "condition": {
          "nodeId": "1",
          "nodeType": "operator",
          "operator": "OR",
          "operands": [
            {
              "nodeId": "1a",
              "nodeType": "atomic",
              "atomicText": "Use of systemic medications which may affect tear film or vision",
              "omopTable": "drug_exposure",
              "strategy": "This is a general catch-all for any systemic medication that could interfere with the study's primary endpoints related to tear film or vision, requiring clinical review.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "requires_manual"
            },
            {
              "nodeId": "1b",
              "nodeType": "atomic",
              "atomicText": "Use of flax seed oil",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to flax seed oil.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "partially_queryable"
            },
            {
              "nodeId": "1c",
              "nodeType": "atomic",
              "atomicText": "Use of fish oil",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to fish oil.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "partially_queryable",
              "clinicalConceptGroup": "omega3_supplements"
            },
            {
              "nodeId": "1d",
              "nodeType": "atomic",
              "atomicText": "Use of omega-3 supplements",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to omega-3 supplements.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "partially_queryable",
              "clinicalConceptGroup": "omega3_supplements"
            },
            {
              "nodeId": "1e",
              "nodeType": "atomic",
              "atomicText": "Use of cyclosporine",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to cyclosporine.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable"
            },
            {
              "nodeId": "1f",
              "nodeType": "atomic",
              "atomicText": "Use of antihistamines",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to the antihistamine class.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable"
            },
            {
              "nodeId": "1g",
              "nodeType": "atomic",
              "atomicText": "Use of cholinergic agents",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to the cholinergic agent class.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable"
            },
            {
              "nodeId": "1h",
              "nodeType": "atomic",
              "atomicText": "Use of anticholinergics",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to the anticholinergic class.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "anticholinergic_agents"
            },
            {
              "nodeId": "1i",
              "nodeType": "atomic",
              "atomicText": "Use of antimuscarinics",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to the antimuscarinic class.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "anticholinergic_agents"
            },
            {
              "nodeId": "1j",
              "nodeType": "atomic",
              "atomicText": "Use of beta-blocking agents",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to the beta-blocker class.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable"
            },
            {
              "nodeId": "1k",
              "nodeType": "atomic",
              "atomicText": "Use of tricyclic antidepressants",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to the tricyclic antidepressant class.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable"
            },
            {
              "nodeId": "1l",
              "nodeType": "atomic",
              "atomicText": "Use of phenothiazines",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to the phenothiazine class.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable"
            },
            {
              "nodeId": "1m",
              "nodeType": "atomic",
              "atomicText": "Use of estrogen-progesterone",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to combination estrogen-progesterone therapies.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "estrogen_derivatives"
            },
            {
              "nodeId": "1n",
              "nodeType": "atomic",
              "atomicText": "Use of other estrogen derivatives",
              "omopTable": "drug_exposure",
              "strategy": "Query for drug exposures to other estrogen derivatives.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "estrogen_derivatives"
            }
          ]
        },
        "requirement": {
          "nodeId": "2",
          "nodeType": "operator",
          "operator": "AND",
          "operands": [
            {
              "nodeId": "2a",
              "nodeType": "atomic",
              "atomicText": "Medication used at a stable dose for at least 3 months prior to screening",
              "omopTable": "drug_exposure",
              "timeConstraint": "for at least 3 months prior to screening",
              "timeFrameStructured": {
                "value": 3,
                "unit": "months",
                "operator": "before",
                "relativeEvent": "screening"
              },
              "strategy": "Requires manual review of medication history to confirm the dose has been stable for the specified duration leading up to the screening visit.",
              "clinicalCategory": "prior_therapy",
              "queryableStatus": "requires_manual"
            },
            {
              "nodeId": "2b",
              "nodeType": "operator",
              "operator": "NOT",
              "operands": [
                {
                  "nodeId": "2b1",
                  "nodeType": "atomic",
                  "atomicText": "Medication dosage was expected to change during the course of the study",
                  "omopTable": "observation",
                  "strategy": "Requires confirmation at screening that there is no plan to alter the dosage of the specified medication during the study period.",
                  "clinicalCategory": "prior_therapy",
                  "queryableStatus": "screening_only"
                }
              ]
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 18,
        "textSnippet": "6 zones based on the modified NEI grading scheme (score range = 0 to 5 per\nzone)\n\u2022 Use of systemic medications (over-the-counter, herbal, prescription, or\nnutritional supplements for dry eyes), which may have affected tear film or\nvision (including but not limited to the following: flax seed oil, fish oil,\nomega-3 supplements, cyclosporine, antihistamines, cholinergic agents,\nanticholinergics, antimuscarines, beta-blocking agents, tricyclic\nantidepressants, phenothiazines, estrogen-progestero...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E11",
      "originalText": "Presence of 1 or more of the following ocular conditions in at least 1 eye:\n\n\u25cb Active ocular infection or non-keratoconjunctivitis sicca (KCS) ocular inflammation\n\n\u039f Active ocular allergy",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion requires one or more of several ocular conditions, which translates to a top-level OR operator. The condition 'non-keratoconjunctivitis sicca (KCS) ocular inflammation' is decomposed into a nested AND operator, requiring the presence of 'ocular inflammation' and the explicit absence (using a NOT operator) of 'keratoconjunctivitis sicca'.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Active ocular infection in at least 1 eye",
            "omopTable": "condition_occurrence",
            "strategy": "Identifies patients with an active eye infection.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "fully_queryable"
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "AND",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "Active ocular inflammation in at least 1 eye",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies patients with active eye inflammation.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "ocular_inflammation"
              },
              {
                "nodeId": "2b",
                "nodeType": "operator",
                "operator": "NOT",
                "operands": [
                  {
                    "nodeId": "2b1",
                    "nodeType": "atomic",
                    "atomicText": "Keratoconjunctivitis sicca (KCS) in at least 1 eye",
                    "omopTable": "condition_occurrence",
                    "strategy": "Excludes patients whose inflammation is specifically KCS (dry eye syndrome).",
                    "clinicalCategory": "safety_exclusion",
                    "queryableStatus": "fully_queryable",
                    "clinicalConceptGroup": "ocular_inflammation"
                  }
                ]
              }
            ]
          },
          {
            "nodeId": "3",
            "nodeType": "atomic",
            "atomicText": "Active ocular allergy in at least 1 eye",
            "omopTable": "condition_occurrence",
            "strategy": "Identifies patients with an active eye allergy.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "fully_queryable"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 18,
        "textSnippet": "the course of the study\n\u2022 Presence of 1 or more of the following ocular conditions in at least 1 eye:\n\u25cb Active ocular infection or non-keratoconjunctivitis sicca (KCS) ocular\ninflammation\n\u039f Active ocular allergy",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E12",
      "originalText": "History of recurrent herpes keratitis or active disease within 6 months prior to Screening Visit",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion is decomposed using an OR operator to connect two conditions. The first condition is a lifelong history of recurrent herpes keratitis, represented as a single atomic node. The second condition is active herpes keratitis within a specific timeframe, which is represented by an atomic node wrapped in a temporal node.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "History of recurrent herpes keratitis",
            "omopTable": "condition_occurrence",
            "strategy": "Identifies any patient with a diagnosis code for recurrent herpes keratitis at any time in their history.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "fully_queryable",
            "clinicalConceptGroup": "herpes_keratitis"
          },
          {
            "nodeId": "2",
            "nodeType": "temporal",
            "temporalConstraint": {
              "operator": "WITHIN",
              "anchor": "Screening Visit",
              "value": 6,
              "unit": "months"
            },
            "operand": {
              "nodeId": "2a",
              "nodeType": "atomic",
              "atomicText": "Active herpes keratitis",
              "omopTable": "condition_occurrence",
              "timeConstraint": "within 6 months prior to Screening Visit",
              "timeFrameStructured": {
                "value": 6,
                "unit": "months",
                "operator": "within",
                "relativeEvent": "Screening Visit"
              },
              "strategy": "Identifies patients with a recent, active episode of herpes keratitis. The 'active' status may require additional clinical context or specific codes indicating an acute event.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "partially_queryable",
              "clinicalConceptGroup": "herpes_keratitis"
            }
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 18,
        "textSnippet": "inflammation\n\u039f Active ocular allergy\nHistory of recurrent herpes keratitis or active disease within 6 months prior to\nScreening Visit",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E13",
      "originalText": "Corneal disorder or abnormality that affected corneal sensitivity or normal spreading of the tear film (except superficial punctate keratitis)",
      "type": "Exclusion",
      "logicOperator": "EXCEPT",
      "decompositionStrategy": "The criterion is structured as a main condition with a specific exclusion. This is modeled using an EXCEPT operator. The main condition itself is complex, requiring both a diagnosis ('Corneal disorder or abnormality') and a resulting functional impact ('affected corneal sensitivity or normal spreading of the tear film'), which translates to an AND operator with a nested OR.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "EXCEPT",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "operator",
            "operator": "AND",
            "operands": [
              {
                "nodeId": "1a",
                "nodeType": "atomic",
                "atomicText": "Corneal disorder or abnormality",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies any diagnosed disorder or structural abnormality of the cornea.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "fully_queryable"
              },
              {
                "nodeId": "1b",
                "nodeType": "operator",
                "operator": "OR",
                "operands": [
                  {
                    "nodeId": "1b1",
                    "nodeType": "atomic",
                    "atomicText": "Corneal sensitivity affected",
                    "omopTable": "observation",
                    "strategy": "Identifies findings related to abnormal or reduced corneal sensitivity, which may require manual chart review to confirm.",
                    "clinicalCategory": "safety_exclusion",
                    "queryableStatus": "requires_manual"
                  },
                  {
                    "nodeId": "1b2",
                    "nodeType": "atomic",
                    "atomicText": "Normal spreading of the tear film affected",
                    "omopTable": "observation",
                    "strategy": "Identifies conditions like dry eye syndrome or abnormal tear film break-up time, which may require manual chart review to confirm.",
                    "clinicalCategory": "safety_exclusion",
                    "queryableStatus": "requires_manual"
                  }
                ]
              }
            ]
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Superficial punctate keratitis",
            "omopTable": "condition_occurrence",
            "strategy": "This is a specific, often transient, condition that is explicitly exempted from the main exclusion criterion.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "fully_queryable"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 18,
        "textSnippet": "Screening Visit\n\u2022 Corneal disorder or abnormality that affected corneal sensitivity or normal\nspreading of the tear film (except superficial punctate keratitis)",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E14",
      "originalText": "Severe blepharitis or obvious inflammation of the lid margin, which in the judgment of the investigator, may have interfered with the interpretation of the study results",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is decomposed into a primary AND structure. The first operand is an OR group containing the two clinical conditions ('Severe blepharitis' or 'obvious inflammation of the lid margin'). The second operand is the qualifying clause that these conditions must be judged by the investigator to potentially interfere with study results.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "1a",
                "nodeType": "atomic",
                "atomicText": "Severe blepharitis",
                "omopTable": "condition_occurrence",
                "strategy": "Identify a diagnosis of blepharitis. The 'severe' modifier requires clinical assessment.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "partially_queryable",
                "clinicalConceptGroup": "lid_margin_inflammation"
              },
              {
                "nodeId": "1b",
                "nodeType": "atomic",
                "atomicText": "Obvious inflammation of the lid margin",
                "omopTable": "condition_occurrence",
                "strategy": "Identify a diagnosis or clinical finding of inflammation of the eyelid margin. The 'obvious' modifier requires clinical assessment.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "partially_queryable",
                "clinicalConceptGroup": "lid_margin_inflammation"
              }
            ]
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Condition may have interfered with the interpretation of the study results in the judgment of the investigator",
            "omopTable": "observation",
            "strategy": "This is a subjective assessment made by the clinical investigator at the time of screening and cannot be queried from standard EHR data.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 18,
        "textSnippet": "spreading of the tear film (except superficial punctate keratitis)\n\u2022 Severe blepharitis or obvious inflammation of the lid margin, which in the\njudgment of the investigator, may have interfered with the interpretation of the\nstudy results",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E15",
      "originalText": "Keratoconjunctivitis sicca secondary to the destruction of conjunctival goblet cells, such as occurs with vitamin A deficiency or scarring such as that with cicatricial pemphigoid, alkali burns, Stevens-Johnson syndrome, trachoma, or irradiation",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion defines a specific type of Keratoconjunctivitis sicca (KCS) by its underlying cause. This is decomposed as a primary AND condition: the patient must have KCS, AND the KCS must be caused by one of several specified conditions, which are handled by a nested OR list.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Keratoconjunctivitis sicca",
            "omopTable": "condition_occurrence",
            "strategy": "Identifies patients with the primary diagnosis of interest.",
            "clinicalCategory": "disease_indication",
            "queryableStatus": "fully_queryable"
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "Vitamin A deficiency",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies an underlying cause of KCS involving destruction of conjunctival goblet cells.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "kcs_etiology"
              },
              {
                "nodeId": "2b",
                "nodeType": "atomic",
                "atomicText": "Cicatricial pemphigoid",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies an underlying scarring cause of KCS involving destruction of conjunctival goblet cells.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "kcs_etiology"
              },
              {
                "nodeId": "2c",
                "nodeType": "atomic",
                "atomicText": "Alkali burn of the eye",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies an underlying scarring cause of KCS involving destruction of conjunctival goblet cells.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "kcs_etiology"
              },
              {
                "nodeId": "2d",
                "nodeType": "atomic",
                "atomicText": "Stevens-Johnson syndrome",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies an underlying scarring cause of KCS involving destruction of conjunctival goblet cells.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "kcs_etiology"
              },
              {
                "nodeId": "2e",
                "nodeType": "atomic",
                "atomicText": "Trachoma",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies an underlying scarring cause of KCS involving destruction of conjunctival goblet cells.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "kcs_etiology"
              },
              {
                "nodeId": "2f",
                "nodeType": "atomic",
                "atomicText": "History of therapeutic irradiation to head or neck",
                "omopTable": "procedure_occurrence",
                "strategy": "Identifies an underlying cause of KCS involving destruction of conjunctival goblet cells.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "partially_queryable",
                "clinicalConceptGroup": "kcs_etiology"
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 18,
        "textSnippet": "study results\n\u2022 Keratoconjunctivitis sicca secondary to the destruction of conjunctival goblet\ncells, such as occurs with vitamin A deficiency or scarring such as that with\ncicatricial pemphigoid, alkali burns, Stevens-Johnson syndrome, trachoma, or\nirradiation",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E16",
      "originalText": "Substantial non-KCS keratitis with overlying corneal stain or other significant corneal findings not directly related to dry eye; in addition, patients with dry eye signs/symptoms (e.g., filamentary keratitis) of a severity where topical monotherapy with an artificial tear would have been inappropriate",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion describes two distinct patient populations separated by a semicolon. The phrase 'in addition' can be ambiguous, but interpreting it as AND would create a contradictory requirement for a patient to have both a non-dry-eye and a dry-eye condition. Therefore, a top-level OR operator is used to represent two eligible groups: (1) patients with specific non-dry-eye corneal findings, or (2) patients with severe dry eye symptoms.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1a",
            "nodeType": "operator",
            "operator": "AND",
            "operands": [
              {
                "nodeId": "1a1",
                "nodeType": "atomic",
                "atomicText": "Substantial non-KCS keratitis",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies patients with significant inflammation of the cornea not caused by dry eye (Keratoconjunctivitis Sicca). The 'substantial' modifier requires clinical assessment.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "requires_manual"
              },
              {
                "nodeId": "1a2",
                "nodeType": "atomic",
                "atomicText": "Overlying corneal stain",
                "omopTable": "observation",
                "strategy": "Confirms epithelial damage associated with the keratitis, typically assessed via fluorescein staining.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "requires_manual"
              }
            ]
          },
          {
            "nodeId": "1b",
            "nodeType": "operator",
            "operator": "AND",
            "operands": [
              {
                "nodeId": "1b1",
                "nodeType": "atomic",
                "atomicText": "Other significant corneal findings",
                "omopTable": "condition_occurrence",
                "strategy": "A catch-all for other clinically important corneal issues that are not specified. Requires manual review.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "requires_manual"
              },
              {
                "nodeId": "1b2",
                "nodeType": "operator",
                "operator": "NOT",
                "operands": [
                  {
                    "nodeId": "1b2a",
                    "nodeType": "atomic",
                    "atomicText": "Corneal findings are directly related to dry eye",
                    "omopTable": "condition_occurrence",
                    "strategy": "Excludes findings that are a manifestation of dry eye disease from this specific sub-clause.",
                    "clinicalCategory": "disease_indication",
                    "queryableStatus": "requires_manual"
                  }
                ]
              }
            ]
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "AND",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "operator",
                "operator": "OR",
                "operands": [
                  {
                    "nodeId": "2a1",
                    "nodeType": "atomic",
                    "atomicText": "Dry eye signs or symptoms present",
                    "omopTable": "condition_occurrence",
                    "strategy": "Identifies the general population with dry eye disease based on clinical signs or patient-reported symptoms.",
                    "clinicalCategory": "disease_indication",
                    "queryableStatus": "partially_queryable"
                  },
                  {
                    "nodeId": "2a2",
                    "nodeType": "atomic",
                    "atomicText": "Filamentary keratitis",
                    "omopTable": "condition_occurrence",
                    "strategy": "Identifies a specific, severe sign of dry eye disease that has a corresponding diagnosis code.",
                    "clinicalCategory": "disease_indication",
                    "queryableStatus": "fully_queryable"
                  }
                ]
              },
              {
                "nodeId": "2b",
                "nodeType": "operator",
                "operator": "NOT",
                "operands": [
                  {
                    "nodeId": "2b1",
                    "nodeType": "atomic",
                    "atomicText": "Severity of dry eye signs/symptoms is appropriate for topical monotherapy with an artificial tear",
                    "omopTable": "observation",
                    "strategy": "This clause selects for patients with severe dry eye, defined as being beyond the point where simple artificial tears alone would be considered adequate treatment. This is a clinical judgment.",
                    "clinicalCategory": "disease_indication",
                    "queryableStatus": "requires_manual"
                  }
                ]
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 18,
        "textSnippet": "irradiation\n\u2022\nSubstantial non-KCS keratitis with overlying corneal stain or other significant\ncorneal findings not directly related to dry eye; in addition, patients with dry\neye signs/symptoms (e.g., filamentary keratitis) of a severity where topical\nmonotherapy with an artificial tear would have been inappropriate",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E17",
      "originalText": "Occlusion of the lacrimal puncta for either eye, with punctal plugs or cauterization < 3 months prior to Screening Visit",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion describes a single event (occlusion) that must occur within a specific time frame. The event can be caused by one of two procedures (punctal plugs OR cauterization). This is modeled as a temporal node wrapping an OR operator, which in turn contains two atomic nodes for the respective procedures.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "temporal",
        "temporalConstraint": {
          "operator": "WITHIN",
          "anchor": "Screening Visit",
          "value": 3,
          "unit": "months"
        },
        "operand": {
          "nodeId": "1",
          "nodeType": "operator",
          "operator": "OR",
          "operands": [
            {
              "nodeId": "1a",
              "nodeType": "atomic",
              "atomicText": "Occlusion of the lacrimal puncta with punctal plugs",
              "omopTable": "procedure_occurrence",
              "timeConstraint": "< 3 months prior to Screening Visit",
              "strategy": "Identifies patients who have had a procedure to block the tear duct with a plug.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "lacrimal_puncta_occlusion"
            },
            {
              "nodeId": "1b",
              "nodeType": "atomic",
              "atomicText": "Occlusion of the lacrimal puncta with cauterization",
              "omopTable": "procedure_occurrence",
              "timeConstraint": "< 3 months prior to Screening Visit",
              "strategy": "Identifies patients who have had a procedure to block the tear duct with cauterization.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "lacrimal_puncta_occlusion"
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 18,
        "textSnippet": "monotherapy with an artificial tear would have been inappropriate\n\u2022 Occlusion of the lacrimal puncta for either eye, with punctal plugs or\ncauterization < 3 months prior to Screening Visit",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E18",
      "originalText": "History of prior ocular/ophthalmic surgery or trauma, which could affect corneal sensitivity and/or tear distribution (e.g., cataract surgery, laser-assisted in situ keratomileusis [LASIK], photorefractive keratectomy, or any surgery involving a limbal or corneal incision) within 6 months prior to at Screening Visit",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion describes a set of ocular/ophthalmic surgeries or traumas that are exclusionary if they occurred within a specific timeframe. The logic is an OR condition for the various events, all wrapped within a single temporal constraint of 'within 6 months prior to Screening Visit'.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "temporal",
        "temporalConstraint": {
          "operator": "WITHIN",
          "anchor": "Screening Visit",
          "value": 6,
          "unit": "months"
        },
        "operand": {
          "nodeId": "1",
          "nodeType": "operator",
          "operator": "OR",
          "operands": [
            {
              "nodeId": "1a",
              "nodeType": "atomic",
              "atomicText": "History of ocular/ophthalmic trauma",
              "omopTable": "condition_occurrence",
              "strategy": "Identifies patients with a history of eye trauma, which could affect study endpoints like corneal sensitivity or tear distribution.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "prior_ocular_procedure_or_trauma"
            },
            {
              "nodeId": "1b",
              "nodeType": "atomic",
              "atomicText": "Cataract surgery",
              "omopTable": "procedure_occurrence",
              "strategy": "Identifies patients with a history of cataract surgery, an example of a procedure that could affect study endpoints.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "prior_ocular_procedure_or_trauma"
            },
            {
              "nodeId": "1c",
              "nodeType": "atomic",
              "atomicText": "Laser-assisted in situ keratomileusis (LASIK)",
              "omopTable": "procedure_occurrence",
              "strategy": "Identifies patients with a history of LASIK, an example of a procedure that could affect study endpoints.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "prior_ocular_procedure_or_trauma"
            },
            {
              "nodeId": "1d",
              "nodeType": "atomic",
              "atomicText": "Photorefractive keratectomy",
              "omopTable": "procedure_occurrence",
              "strategy": "Identifies patients with a history of photorefractive keratectomy, an example of a procedure that could affect study endpoints.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable",
              "clinicalConceptGroup": "prior_ocular_procedure_or_trauma"
            },
            {
              "nodeId": "1e",
              "nodeType": "atomic",
              "atomicText": "Any surgery involving a limbal or corneal incision",
              "omopTable": "procedure_occurrence",
              "strategy": "A broader category to capture other relevant ocular surgeries not explicitly listed that involve incisions that could affect study endpoints.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "partially_queryable",
              "clinicalConceptGroup": "prior_ocular_procedure_or_trauma"
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 19,
        "textSnippet": "\u2022 History of prior ocular/ophthalmic surgery or trauma, which could affect\ncorneal sensitivity and/or tear distribution (e.g., cataract surgery, laser-assisted\nin situ keratomileusis [LASIK], photorefractive keratectomy, or any surgery\ninvolving a limbal or corneal incision) within 6 months prior to at Screening\nVisit",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E19",
      "originalText": "Patients who were currently using topical ocular medication or had used topical ocular medication within 2 weeks of Screening Visit; however, patients who were being treated bilaterally with the following could have been considered:\n\n\u039f Current use of a marketed artificial tear, which was to have been discontinued at the Screening Visit\n\n\u25cb Monotherapy for glaucoma or OHT using a prostaglandin analog, beta-blocker, alpha-2 agonist, or carbonic anhydrase inhibitors; any topical IOP-lowering medications must have had a start date of \u2265 3 months prior to Screening Visit and the dosage was not expected to change during the study\n\n\u039f If using any form of topical ophthalmic cyclosporine (i.e., RESTASIS\u00ae), lifitegrast 5% ophthalmic solution (Xiidra\u00ae), for less than 90 days prior to Screening Visit",
      "type": "Exclusion",
      "logicOperator": "EXCEPT",
      "decompositionStrategy": "The criterion is structured as an exclusion with exceptions. This is best represented by an EXCEPT operator, where the first operand defines the broad excluded group (recent topical ocular medication users) and the second operand defines the specific medication scenarios that are permitted.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "EXCEPT",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "1a",
                "nodeType": "atomic",
                "atomicText": "Currently using topical ocular medication",
                "omopTable": "drug_exposure",
                "timeConstraint": "current use at Screening Visit",
                "strategy": "Identifies patients with ongoing use of any topical ocular medication at the time of screening.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "requires_manual"
              },
              {
                "nodeId": "1b",
                "nodeType": "temporal",
                "temporalConstraint": {
                  "operator": "WITHIN",
                  "anchor": "Screening Visit",
                  "value": 2,
                  "unit": "weeks"
                },
                "operand": {
                  "nodeId": "1b1",
                  "nodeType": "atomic",
                  "atomicText": "Used topical ocular medication",
                  "omopTable": "drug_exposure",
                  "timeFrameStructured": {
                    "value": 2,
                    "unit": "weeks",
                    "operator": "within",
                    "relativeEvent": "Screening Visit"
                  },
                  "strategy": "Identifies patients with recent use of any topical ocular medication leading up to screening.",
                  "clinicalCategory": "safety_exclusion",
                  "queryableStatus": "fully_queryable"
                }
              }
            ]
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "Current bilateral use of a marketed artificial tear, to be discontinued at the Screening Visit",
                "omopTable": "drug_exposure",
                "strategy": "Allows patients using artificial tears, with the procedural requirement that they are stopped.",
                "clinicalCategory": "prior_therapy",
                "queryableStatus": "requires_manual",
                "clinicalConceptGroup": "allowed_meds"
              },
              {
                "nodeId": "2b",
                "nodeType": "operator",
                "operator": "AND",
                "operands": [
                  {
                    "nodeId": "2b1",
                    "nodeType": "atomic",
                    "atomicText": "Bilateral monotherapy for glaucoma or OHT",
                    "omopTable": "drug_exposure",
                    "strategy": "Identifies patients on a single, stable therapy for glaucoma or OHT.",
                    "clinicalCategory": "prior_therapy",
                    "queryableStatus": "partially_queryable",
                    "clinicalConceptGroup": "allowed_meds"
                  },
                  {
                    "nodeId": "2b2",
                    "nodeType": "operator",
                    "operator": "OR",
                    "operands": [
                      {
                        "nodeId": "2b2a",
                        "nodeType": "atomic",
                        "atomicText": "Use of a prostaglandin analog",
                        "omopTable": "drug_exposure",
                        "strategy": "Specifies an allowed class of glaucoma medication.",
                        "clinicalCategory": "prior_therapy",
                        "queryableStatus": "fully_queryable",
                        "clinicalConceptGroup": "glaucoma_monotherapy_class"
                      },
                      {
                        "nodeId": "2b2b",
                        "nodeType": "atomic",
                        "atomicText": "Use of a beta-blocker",
                        "omopTable": "drug_exposure",
                        "strategy": "Specifies an allowed class of glaucoma medication.",
                        "clinicalCategory": "prior_therapy",
                        "queryableStatus": "fully_queryable",
                        "clinicalConceptGroup": "glaucoma_monotherapy_class"
                      },
                      {
                        "nodeId": "2b2c",
                        "nodeType": "atomic",
                        "atomicText": "Use of an alpha-2 agonist",
                        "omopTable": "drug_exposure",
                        "strategy": "Specifies an allowed class of glaucoma medication.",
                        "clinicalCategory": "prior_therapy",
                        "queryableStatus": "fully_queryable",
                        "clinicalConceptGroup": "glaucoma_monotherapy_class"
                      },
                      {
                        "nodeId": "2b2d",
                        "nodeType": "atomic",
                        "atomicText": "Use of a carbonic anhydrase inhibitor",
                        "omopTable": "drug_exposure",
                        "strategy": "Specifies an allowed class of glaucoma medication.",
                        "clinicalCategory": "prior_therapy",
                        "queryableStatus": "fully_queryable",
                        "clinicalConceptGroup": "glaucoma_monotherapy_class"
                      }
                    ]
                  },
                  {
                    "nodeId": "2b3",
                    "nodeType": "atomic",
                    "atomicText": "Start date of topical IOP-lowering medication is >= 3 months prior to Screening Visit",
                    "omopTable": "drug_exposure",
                    "timeConstraint": "start date >= 3 months prior to Screening Visit",
                    "timeFrameStructured": {
                      "value": 3,
                      "unit": "months",
                      "operator": "before",
                      "relativeEvent": "Screening Visit"
                    },
                    "strategy": "Ensures the allowed glaucoma therapy is stable and long-term.",
                    "clinicalCategory": "prior_therapy",
                    "queryableStatus": "fully_queryable"
                  },
                  {
                    "nodeId": "2b4",
                    "nodeType": "operator",
                    "operator": "NOT",
                    "operands": [
                      {
                        "nodeId": "2b4a",
                        "nodeType": "atomic",
                        "atomicText": "Dosage of topical IOP-lowering medication is expected to change during the study",
                        "omopTable": "observation",
                        "strategy": "Ensures stability of the allowed glaucoma therapy throughout the study.",
                        "clinicalCategory": "prior_therapy",
                        "queryableStatus": "requires_manual"
                      }
                    ]
                  }
                ]
              },
              {
                "nodeId": "2c",
                "nodeType": "operator",
                "operator": "AND",
                "operands": [
                  {
                    "nodeId": "2c1",
                    "nodeType": "operator",
                    "operator": "OR",
                    "operands": [
                      {
                        "nodeId": "2c1a",
                        "nodeType": "atomic",
                        "atomicText": "Use of any form of topical ophthalmic cyclosporine (e.g., RESTASIS\u00ae)",
                        "omopTable": "drug_exposure",
                        "strategy": "Identifies use of a specific allowed immunomodulatory agent.",
                        "clinicalCategory": "prior_therapy",
                        "queryableStatus": "fully_queryable",
                        "clinicalConceptGroup": "allowed_meds_short_term"
                      },
                      {
                        "nodeId": "2c1b",
                        "nodeType": "atomic",
                        "atomicText": "Use of lifitegrast 5% ophthalmic solution (Xiidra\u00ae)",
                        "omopTable": "drug_exposure",
                        "strategy": "Identifies use of a specific allowed immunomodulatory agent.",
                        "clinicalCategory": "prior_therapy",
                        "queryableStatus": "fully_queryable",
                        "clinicalConceptGroup": "allowed_meds_short_term"
                      }
                    ]
                  },
                  {
                    "nodeId": "2c2",
                    "nodeType": "atomic",
                    "atomicText": "Duration of use is less than 90 days prior to Screening Visit",
                    "omopTable": "drug_exposure",
                    "timeConstraint": "duration of therapy < 90 days prior to Screening Visit",
                    "timeFrameStructured": {
                      "value": 90,
                      "unit": "days",
                      "operator": "<",
                      "relativeEvent": "Screening Visit"
                    },
                    "strategy": "Restricts the exception to patients who have been on the therapy for a relatively short duration.",
                    "clinicalCategory": "prior_therapy",
                    "queryableStatus": "fully_queryable"
                  }
                ]
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 19,
        "textSnippet": "Visit\n\u2022 Patients who were currently using topical ocular medication or had used\ntopical ocular medication within 2 weeks of Screening Visit; however, patients\nwho were being treated bilaterally with the following could have been\nconsidered:\n\u039f Current use of a marketed artificial tear, which was to have been\ndiscontinued at the Screening Visit\n\u2022 Monotherapy for glaucoma or OHT using a prostaglandin analog, beta-\nblocker, alpha-2 agonist, or carbonic anhydrase inhibitors; any topical\nIOP-loweri...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E20",
      "originalText": "Patients who were currently being treated with both IOP-lowering medication and any form of topical ophthalmic cyclosporine (i.e., RESTASIS\u00ae) or lifitegrast 5% ophthalmic solution (Xiidra\u00ae) or generic of these medications cannot be enrolled",
      "type": "Exclusion",
      "logicOperator": "NOT",
      "decompositionStrategy": "The criterion is an exclusion, indicated by 'cannot be enrolled'. This is modeled with a root NOT operator. The condition for exclusion is the concurrent use of two types of medications ('both...and...'), which is represented by an AND operator. The second medication type is a list of alternatives ('...or...'), which is captured by a nested OR operator.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "NOT",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "operator",
            "operator": "AND",
            "operands": [
              {
                "nodeId": "1a",
                "nodeType": "atomic",
                "atomicText": "Currently being treated with IOP-lowering medication",
                "omopTable": "drug_exposure",
                "timeConstraint": "currently being treated",
                "strategy": "Identify patients on any medication intended to lower intraocular pressure.",
                "clinicalCategory": "prior_therapy",
                "queryableStatus": "fully_queryable"
              },
              {
                "nodeId": "1b",
                "nodeType": "operator",
                "operator": "OR",
                "operands": [
                  {
                    "nodeId": "1b1",
                    "nodeType": "atomic",
                    "atomicText": "Currently being treated with any form of topical ophthalmic cyclosporine (including RESTASIS\u00ae and generics)",
                    "omopTable": "drug_exposure",
                    "timeConstraint": "currently being treated",
                    "strategy": "Identify use of cyclosporine ophthalmic solutions, covering both brand and generic formulations.",
                    "clinicalCategory": "prior_therapy",
                    "queryableStatus": "fully_queryable",
                    "clinicalConceptGroup": "prohibited_dry_eye_meds"
                  },
                  {
                    "nodeId": "1b2",
                    "nodeType": "atomic",
                    "atomicText": "Currently being treated with lifitegrast 5% ophthalmic solution (including Xiidra\u00ae and generics)",
                    "omopTable": "drug_exposure",
                    "timeConstraint": "currently being treated",
                    "strategy": "Identify use of lifitegrast ophthalmic solutions, covering both brand and generic formulations.",
                    "clinicalCategory": "prior_therapy",
                    "queryableStatus": "fully_queryable",
                    "clinicalConceptGroup": "prohibited_dry_eye_meds"
                  }
                ]
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 19,
        "textSnippet": "Screening Visit\n\u2022 Patients who were currently being treated with both IOP-lowering medication\nand any form of topical ophthalmic cyclosporine (i.e., RESTASIS\u00ae) or\nlifitegrast 5% ophthalmic solution (Xiidra\u00ae) or generic of these medications\ncannot be enrolled",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_E21",
      "originalText": "Patient had a condition or is in a situation, which in the investigator's opinion, may have put the patient at significant risk, may have confounded the study results, or may have interfered significantly with the patient's participation in the study",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion is a disjunction (OR) of three distinct reasons for exclusion, all of which are based on the investigator's subjective opinion. Each reason is treated as a separate atomic condition, resulting in an OR operator with three child nodes. These conditions are not queryable from structured data.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Investigator opinion: patient has a condition or situation that may put them at significant risk",
            "omopTable": "observation",
            "strategy": "This is a general safety exclusion based on the investigator's clinical judgment to protect the patient's well-being.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "investigator_discretion_exclusion"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Investigator opinion: patient has a condition or situation that may confound the study results",
            "omopTable": "observation",
            "strategy": "This clause ensures data integrity by excluding patients whose underlying conditions could interfere with the interpretation of the study's findings.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "investigator_discretion_exclusion"
          },
          {
            "nodeId": "3",
            "nodeType": "atomic",
            "atomicText": "Investigator opinion: patient has a condition or situation that may interfere significantly with study participation",
            "omopTable": "observation",
            "strategy": "This clause ensures protocol compliance and feasibility by excluding patients who may not be able to complete all study procedures.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "investigator_discretion_exclusion"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 19,
        "textSnippet": "lifitegrast 5% ophthalmic solution (Xiidra\u00ae) or generic of these medications\ncannot be enrolled\n\u2022\nPatient had a condition or is in a situation, which in the investigator's opinion,\nmay have put the patient at significant risk, may have confounded the study\nresults, or may have interfered significantly with the patient's participation in\nthe study",
        "confidence": 1.0
      }
    }
  ],
  "counts": {
    "criteria": 33,
    "atomics": 125,
    "options": 0
  },
  "errors": []
}